2024
Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series
Li Y, Msaouel P, Campbell M, Hwu P, Diab A, Kim S. Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series. RMD Open 2024, 10: e004308. PMID: 39214611, PMCID: PMC11367333, DOI: 10.1136/rmdopen-2024-004308.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsImmune checkpoint inhibitor therapyAnti-IL-17A antibodyAdverse eventsAnti-PD-1 antibody monotherapyInterleukin (IL)-17/IL-23 axisPsoriatic arthritisImmune checkpoint inhibitor treatmentPD-1 antibody therapyResponse to ICI therapyImmune-related adverse eventsIL-23/IL-17 axisImmune checkpoint inhibitor exposureIL-17/23 axisAnti-CTLA-4Checkpoint inhibitor therapyCell renal cell carcinomaAnti-IL-17AAnti-IL-23 antibodyAssociated with adverse eventsPre-existing psoriasisAnti-tumor efficacyIL-23/IL-17Renal cell carcinomaICI therapyEmerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy
Turner N, Hamidi S, Ouni R, Rico R, Henderson Y, Puche M, Alekseev S, Colunga-Minutti J, Zafereo M, Lai S, Kim S, Cabanillas M, Nurieva R. Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy. Frontiers In Immunology 2024, 15: 1369780. PMID: 38868771, PMCID: PMC11167082, DOI: 10.3389/fimmu.2024.1369780.Peer-Reviewed Original ResearchConceptsAnaplastic thyroid cancerFollicular-derived thyroid cancersAdvanced thyroid cancerThyroid cancerFood and Drug AdministrationManagement of advanced thyroid cancerEra of immunotherapyTargeted kinase inhibitorsU.S Food and Drug AdministrationImmune milieuRefractory diseaseExcellent prognosisTherapeutic optionsTreatment optionsKinase inhibitorsDrug AdministrationGenetic driversTherapeutic avenuesCancerImmunotherapyGenetic landscapeRadioiodineTreatmentMolecular basisOptions
2023
Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept
Aminu M, Daver N, Godoy M, Shroff G, Wu C, Torre-Sada L, Goizueta A, Shannon V, Faiz S, Altan M, Garcia-Manero G, Kantarjian H, Ravandi-Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Naing A, Kim S, Kontoyiannis D, Khawaja F, Chung C, Wu J, Sheshadri A. Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. Frontiers In Immunology 2023, 14: 1249511. PMID: 37841255, PMCID: PMC10570510, DOI: 10.3389/fimmu.2023.1249511.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsGround-glass opacitiesBlood biomarkersImmune checkpoint inhibitor pneumonitisCheckpoint inhibitor pneumonitisAcute myeloid leukemiaPost-test probabilityCheckpoint inhibitorsMyeloid leukemiaCT patternsLung inflammationPneumonitisInfected lungsRelevant blood biomarkersDiagnostic valueLung parenchymaPneumoniaCT imagesBloodBiomarkersPatientsHabitat imagesBlood modelDetection of pneumoniaLeukemiaPneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer
Altan M, Soto F, Xu T, Wilson N, Franco-Vega M, Clavijo C, Shannon V, Faiz S, Gandhi S, Lin S, Lopez P, Zhong L, Akhmedzhanov F, Godoy M, Shroff G, Wu J, Khawaja F, Kim S, Naing A, Heymach J, Daniel-Macdougall C, Liao Z, Sheshadri A. Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer. Clinical Oncology 2023, 35: 630-639. PMID: 37507279, DOI: 10.1016/j.clon.2023.07.003.Peer-Reviewed Original ResearchConceptsLocally advanced non-small cell lung cancerAdvanced non-small cell lung cancerNon-small cell lung cancerImmune checkpoint inhibitionLA-NSCLCCell lung cancerInterstitial lung diseaseCheckpoint inhibitionLung cancerLung diseaseRisk factorsMultivariate Cox proportional hazards modelAssociated with higher all-cause mortalityLA-NSCLC patientsMean radiation doseHazards modelMultivariable cause-specific hazards modelRetrospective chart reviewCox proportional hazards modelsAll-cause mortalityProportional hazards modelCombined chemoradiationConcurrent chemoradiationMedian ageCause-specific hazard modelA Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus-Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation: Proof of Concept
Ostrin E, Rider N, Alousi A, Irajizad E, Li L, Peng Q, Kim S, Bashoura L, Arain M, Noor L, Patel N, Mehta R, Popat U, Hosing C, Jenq R, Rondon G, Hanash S, Paczesny S, Shpall E, Champlin R, Dickey B, Sheshadri A. A Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus-Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation: Proof of Concept. ImmunoHorizons 2023, 7: 421-430. PMID: 37289498, PMCID: PMC10491477, DOI: 10.4049/immunohorizons.2300031.Peer-Reviewed Original ResearchConceptsBronchiolitis obliterans syndromeHematopoietic cell transplantationGraft-versus-host diseaseHematopoietic cell transplant recipientsTransient impairmentCell transplantationNasal inflammationNew-onset bronchiolitis obliterans syndromeChronic graft-versus-host diseaseMultiplex magnetic bead immunoassayNasal mucosal lining fluidAllogeneic hematopoietic cell transplantationMucosal lining fluidInflammatory cytokine signatureType 2 inflammationT cell activationMagnetic bead immunoassayNasal inflammatory responseRespiratory tract inflammationCounterregulatory moleculesBetween-group differencesIL-17ACytokine signatureBead immunoassayClinical criteria
2022
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Hailemichael Y, Johnson D, Abdel-Wahab N, Foo W, Bentebibel S, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, Kim S, Nurieva R, Lazar A, Abu-Sbeih H, Fa'ak F, Mathew A, Wang Y, Falohun A, Trinh V, Zobniw C, Spillson C, Burks J, Awiwi M, Elsayes K, Soto L, Melendez B, Davies M, Wargo J, Curry J, Yee C, Lizee G, Singh S, Sharma P, Allison J, Hwu P, Ekmekcioglu S, Diab A. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 2022, 40: 509-523.e6. PMID: 35537412, PMCID: PMC9221568, DOI: 10.1016/j.ccell.2022.04.004.Peer-Reviewed Original ResearchConceptsImmune checkpoint blockadeExperimental autoimmune encephalomyelitisInterleukin-6 blockadeInterleukin-6Anti-cytotoxic T-lymphocyte-associated antigen 4T-lymphocyte-associated antigen 4Anti-programmed death-1Experimental autoimmune encephalomyelitis symptomsImmune-related adverse eventsICB-treated patientsPromote tumor immunityAnti-CTLA-4Anti-PD-1Improve tumor controlEffector T cellsT helper 1T helper 17Expression of interleukin-6Chemotactic markersImmunotherapy toxicityReduced Th17Antitumor immunityCheckpoint blockadeTumor controlDeath-1Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study
Sheshadri A, Goizueta A, Shannon V, London D, Garcia‐Manero G, Kantarjian H, Ravandi‐Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Zarifa A, Albittar A, Zhong L, Akhmedzhanov F, Arain M, Alfayez M, Alotaibi A, Altan M, Naing A, Mendoza T, Godoy M, Shroff G, Kim S, Faiz S, Kontoyiannis D, Khawaja F, Jennings K, Daver N. Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. Cancer 2022, 128: 2736-2745. PMID: 35452134, PMCID: PMC9232977, DOI: 10.1002/cncr.34229.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsAcute myeloid leukemiaImmune checkpoint inhibitor therapyAcute myeloid leukemia patientsICI-related pneumonitisPneumonitis riskMyeloid leukemiaCheckpoint inhibitorsEffect of immune checkpoint inhibitorsFemale sexReduced T-cell functionRisk factorsMultivariate Cox proportional hazards modelICI-containing regimensMultidisciplinary adjudication committeeRate of pneumonitisCheckpoint inhibitor therapyTreating acute myeloid leukemiaIncreased platelet countIncreased mortalityResponse to therapyT cell functionRetrospective cohort studyAttack cancer cellsCox proportional hazards modelsDistinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Kim S, Chu Y, Misoi M, Suarez-Almazor M, Tayar J, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu S, Wang J, Shah A, Tannir N, Campbell M, Gibbons D, Cascone T, Lu C, Blumenschein G, Altan M, Lim B, Valero V, Loghin M, Tu J, Westin S, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi H, Hwu P, Oliva I, Davies M, Patel S, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications 2022, 13: 1970. PMID: 35413951, PMCID: PMC9005525, DOI: 10.1038/s41467-022-29539-3.Peer-Reviewed Original ResearchConceptsCD8+ T cellsImmune-related adverse eventsImmune checkpoint inhibitorsT cellsCheckpoint inhibitorsAssociated with immune-related adverse eventsPD-1 inhibitor therapyT-cell axisEnhanced Th17Antitumor immunityCTLA-4PD-1Inhibitor therapyImmunomodulatory therapyTCR repertoirePredictive biomarkersPeripheral bloodMyeloid cellsAdverse eventsCell signaturesCancer therapyInflammatory arthritisInflamed jointsTherapyTherapeutic target
2021
Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab
Kim S, Tayar J, Fu S, Ke D, Norry E, Sun A, Miller J, Hong D. Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab. Journal For ImmunoTherapy Of Cancer 2021, 9: e002716. PMID: 34233963, PMCID: PMC8264871, DOI: 10.1136/jitc-2021-002716.Peer-Reviewed Original ResearchConceptsImmune effector cell-associated neurotoxicity syndromeCytokine release syndromeT cellsCell therapyT-cell receptor T cellsTreatment of cytokine release syndromeImmune effector cell therapiesCalcium pyrophosphate dihydrate crystalsFallopian tube cancerT-cell therapyCD4<sup>+</sup> TDeposition of calcium pyrophosphate dihydrate crystalsTCR-T cellsEffector cell therapiesAmount of IL-6Left knee arthritisPresence of calcium pyrophosphate dihydrate crystalsMAGE-A4Th17 cellsNeurotoxicity syndromeCancer responseInterleukin-17IL-6TherapyInflammatory arthritisUse of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis
Kim S, Pundole X, Dadu R, Lambotte O, Ramos-Casals M, Suarez-Almazor M. Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis. Immunotherapy 2021, 13: 465-475. PMID: 33641345, PMCID: PMC7983044, DOI: 10.2217/imt-2020-0272.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsHistory of sarcoidosisPre-existing sarcoidosisCancer patientsCheckpoint inhibitorsRemote historyDose of atezolizumabEvaluate adverse eventsFrequency of flaresICI initiationHilar lymphadenopathySymptomatic exacerbationAdverse eventsSarcoidosisSubcutaneous nodulesPatientsFluctuating courseAtezolizumabCancerInhibitorsUveitisPrednisoneLymphadenopathyExacerbationDoseDistinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications
Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, Balachandran DD, Evans SE, Faiz S, Vazquez W, Divenko M, Mathur R, Tippen SP, Gumbs C, Neelapu SS, Naing A, Wang L, Diab A, Futreal A, Nurieva R, Daver N. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. Frontiers In Immunology 2021, 11: 590494. PMID: 33552049, PMCID: PMC7859512, DOI: 10.3389/fimmu.2020.590494.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsAML/MDS patientsPulmonary complicationsAcute myeloid leukemiaMDS patientsICI groupCheckpoint inhibitorsBronchoalveolar lavageMyelodysplastic syndromeT cellsTh17/Th1 cellsBAL T cellsRisk of pneumonitisBronchoalveolar lavage fluidFungal pneumoniaPulmonary symptomsIL-17Lavage fluidPeripheral bloodTh1 cellsLeukemia patientsMyeloid leukemiaDistinct immunophenotypePatientsComplications
2019
Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare
Kim S, Bittar M, Kim H, Neelapu S, Zurita A, Nurieva R, Suarez-Almazor M. Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare. Journal For ImmunoTherapy Of Cancer 2019, 7: 126. PMID: 31088575, PMCID: PMC6518723, DOI: 10.1186/s40425-019-0597-x.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsCheckpoint inhibitorsNivolumab infusionAdverse eventsIL-17 producing CD4Immune checkpoint inhibitor therapyImmune checkpoint inhibitor treatmentImmune-related adverse eventsPatients treated with nivolumabCD4+ T cellsAmount of IL-17Characterized immune cellsCheckpoint inhibitor treatmentPD-1 inhibitorsCheckpoint inhibitor therapyCrystal arthritisSynovial fluidRenal cell carcinomaAutoimmune inflammatory arthritisT helper 17Neutrophil-driven inflammationProphylactic colchicinePD-1Inhibitor therapyConclusionsThis caseEx Vivo Interferon Gamma Production by Peripheral Immune Cells Predicts Survival in Lung Adenocarcinoma
Ahn S, Kwon M, Sung M, Jung S, Lee S, Park Y, Kim S, Song J. Ex Vivo Interferon Gamma Production by Peripheral Immune Cells Predicts Survival in Lung Adenocarcinoma. Clinical Lung Cancer 2019, 20: e299-e308. PMID: 30824332, DOI: 10.1016/j.cllc.2019.01.002.Peer-Reviewed Original ResearchConceptsIFN-g productionEastern Cooperative Oncology Group performance statusIFN-gLung adenocarcinomaOverall survivalPerformance statusLung cancerAssociated with lung cancer pathogenesisCancer stageProduction of IFN-gReceiver operating characteristic curve analysisStage IV lung cancerCox proportional hazards analysisTreatment-naive patientsAntitumor immune surveillanceOperating characteristics curve analysisOptimal cutoff valueOverall patient survivalInterferon-gamma productionCharacteristic curve analysisIFN-g levelsIV lung cancerProportional hazards analysisStage IV cancerLung cancer pathogenesis
2018
Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists
Kim S, Suarez-Almazor M. Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists. Expert Review Of Clinical Immunology 2018, 15: 211-213. PMID: 30589372, DOI: 10.1080/1744666x.2019.1559731.Peer-Reviewed Original Research
2017
Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series
Kim S, Tayar J, Trinh V, Suarez-Almazor M, Garcia S, Hwu P, Johnson D, Uemura M, Diab A. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Annals Of The Rheumatic Diseases 2017, 76: 2061. PMID: 28830882, DOI: 10.1136/annrheumdis-2017-211560.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsImmune checkpoint inhibitorsCheckpoint inhibitorsReceptor antibodiesAssociated with immune-related adverse eventsMild immune-related adverse eventsEffective alternative to corticosteroidsEfficacy of ICI therapyICI-induced inflammatory arthritisImmune checkpoint inhibitor therapyAnti-IL-6 receptor antibodyAlternative to corticosteroidsTreated with corticosteroidsTreated with tocilizumabTumor necrosis factor-aImmune dampening effectsInflammatory side effectsAlternative therapeutic strategiesFood and Drug AdministrationTreatment of rheumatoid arthritisJuvenile idiopathic arthritisAntitumour responseICI therapyTNFa inhibitorsCheckpoint inhibitionReview: Immune‐Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer
Suarez‐Almazor M, Kim S, Abdel‐Wahab N, Diab A. Review: Immune‐Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer. Arthritis & Rheumatology 2017, 69: 687-699. PMID: 28085999, DOI: 10.1002/art.40043.Peer-Reviewed Original Research
2016
Protein stabilization improves STAT3 function in autosomal dominant hyper-IgE syndrome
Bocchini C, Nahmod K, Katsonis P, Kim S, Kasembeli M, Freeman A, Lichtarge O, Makedonas G, Tweardy D. Protein stabilization improves STAT3 function in autosomal dominant hyper-IgE syndrome. Blood 2016, 128: 3061-3072. PMID: 27799162, PMCID: PMC5201093, DOI: 10.1182/blood-2016-02-702373.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCytokinesDiterpenesDNA-Binding ProteinsHalf-LifeHeat Shock Transcription FactorsHerpesvirus 4, HumanHumansInterleukin-17Job SyndromeMiceModels, MolecularMutant ProteinsMutationPhosphotyrosineProtein BindingProtein StabilitySpleenSTAT3 Transcription FactorTranscription FactorsConceptsAutosomal dominant hyper-IgE syndromeSTAT3 mutationsPeripheral blood mononuclear cellsAD-HIESProtein stabilityEpstein-Barr virus-transformed BPY-STAT3Human peripheral blood mononuclear cellsHeat shock proteinsHyper-IgE syndromeSTAT3 target genesProtein half-lifeMouse splenocytesUpregulating heat shock proteinsAD-HIES patientsLevel of STAT3T cellsDominant-negative mutationsTreatment of human peripheral blood mononuclear cellsCD8<sup>+</sup> T cellsSTAT3 functionEpstein-Barr virus-transformed B cellsProtein functionHuman CD4<sup>+</sup>MRNA levels
2012
Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells
Kinnunen T, Chamberlain N, Morbach H, Choi J, Kim S, Craft J, Mayer L, Cancrini C, Passerini L, Bacchetta R, Ochs HD, Torgerson TR, Meffre E. Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood 2012, 121: 1595-1603. PMID: 23223361, PMCID: PMC3587322, DOI: 10.1182/blood-2012-09-457465.Peer-Reviewed Original ResearchConceptsB cell tolerancePeripheral B cell toleranceIPEX patientsRegulatory T cellsAutoreactive B cellsNaive B cellsB cellsT cellsTreg functionAutoreactive mature naive B cellsHuman B cell toleranceForkhead box protein 3 geneHuman regulatory T cellsMature naive B cellsTreg-like cellsCentral B cell toleranceSevere autoimmune disordersT-cell costimulatorTransitional B cellsRegulation of CD40LReactivity of antibodiesDefective Treg functionSingle B cellsPD-1Autoimmune disorders